The American Society of Clinical Oncology (ASCO) annual meeting in Chicago has highlighted significant progress in treating refractory cancers, specifically through the introduction of RAS(ON) inhibitors and novel immunotherapy enhancers.

在芝加哥舉行的美國臨床腫瘤學會（ASCO）年會，重點介紹了治療難治性癌症的顯著進展，特別是引入了RAS(ON)抑制劑與新型免疫療法增強劑。

A primary focal point of the proceedings was the presentation of Phase 3 trial data for daraxonrasib, a once-daily oral medication developed by Revolution Medicines. The study, published in the New England Journal of Medicine, involved 500 patients with metastatic pancreatic cancer who had previously failed first-line chemotherapy. The administration of daraxonrasib resulted in a median overall survival of 13.2 months, compared to 6.7 months for the chemotherapy cohort, representing a 60% reduction in the risk of death. This therapeutic efficacy is attributed to the drug's capacity to inhibit the mutated KRAS protein, a driver present in over 90% of pancreatic malignancies. Furthermore, the drug demonstrated a superior safety profile; adverse events leading to treatment discontinuation occurred in 1.2% of the daraxonrasib group versus 11% in the chemotherapy group, although cutaneous rashes were reported in approximately 14% of patients.

會議的一個主要焦點是由Revolution Medicines開發的每日一次口服藥 daraxonrasib 的第三期臨床試驗數據。這項發表在《新英格蘭醫學雜誌》的研究涉及500名之前接受過第一線化療但失敗的轉移性胰臟癌患者。使用 daraxonrasib 後，中位總生存期達到13.2個月，而化療組僅為6.7個月，死亡風險降低了60%。這種治療效果歸因於藥物能夠抑制突變的KRAS蛋白，而該蛋白在超過90%的胰臟惡性腫瘤中均為驅動因素。此外，該藥展現了更優越的安全性；daraxonrasib組僅有1.2%的患者因不良事件而停止治療，而化療組則為11%，儘管約14%的患者報告出現皮膚紅疹。

Parallel developments in immunotherapy were evidenced by the trial of GRWD5769, developed by Greywolf Therapeutics. This agent targets the ERAP1 enzyme to prevent tumor cells from evading immune detection, thereby enhancing the efficacy of the immunotherapy cemiplimab. In a trial of 83 patients across multiple jurisdictions, the combination therapy induced tumor shrinkage of at least 30% in 15 participants across six distinct cancer types, including lung and bowel cancers. This mechanism effectively nullifies the 'invisibility' of malignant cells, allowing T-cells to identify and eliminate them.

免疫療法的平行發展則由Greywolf Therapeutics開發的GRWD5769試驗所證明。該藥劑針對ERAP1酶，以防止腫瘤細胞逃避免疫偵測，從而增強免疫療法 cemiplimab 的療效。在一項跨多個司法管轄區、涉及83名患者的試驗中，聯合療法使六種不同癌症（包括肺癌與腸癌）的15名參與者腫瘤縮小了至少30%。此機制有效地消除了惡性細胞的「隱形」狀態，使T細胞能夠識別並清除它們。

Despite these pharmacological advancements, systemic challenges persist. Data indicates a projected global deficit of 100 million cancer care professionals by 2050. Furthermore, there is a documented increase in cancer incidence among cohorts under age 50 in industrialized nations, potentially linked to environmental factors and lifestyle variables. Geopolitically, the ASCO meeting signaled a shift in drug development hegemony, with the emergence of China as a significant biotechnology powerhouse, evidenced by the first headliner presentation based exclusively on Chinese clinical trials.

儘管有這些藥理學上的進步，系統性挑戰依然存在。數據指出，到2050年，全球癌症護理專業人員預計將短缺1億人。此外，工業化國家中50歲以下人群的癌症發病率紀錄顯示有所增加，可能與環境因素及生活方式變數有關。在地緣政治方面，ASCO年會信號出藥物開發霸權的轉移，中國正崛起為重要的生物技術強國，這由首個完全基於中國臨床試驗的主講演講可見一斑。

While daraxonrasib and GRWD5769 offer promising improvements in survival and response rates for hard-to-treat cancers, their clinical integration remains subject to regulatory approval and the resolution of global healthcare staffing shortages.

雖然 daraxonrasib 與 GRWD5769 在生存率與反應率方面為難治性癌症帶來了令人期待的改善，但其臨床整合仍取決於監管部門的批准，以及全球醫療人力短缺問題的解決。